Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STIMULI in limited-stage small cell lung cancer
ACTRN12618000918224Phase 2Completed
- Sponsor
- NHMRC Clinical Trials Centre
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial in small cell lung cancer (SCLC) comparing Nivolumab plus ipilimumab with Observation (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Jan 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ACTRN12618000918224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000918224.